Clinical Cancer Research Targets AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pellat-Deceunynck, C.
Right arrow Articles by Bataille, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pellat-Deceunynck, C.
Right arrow Articles by Bataille, R.
Clinical Cancer Research Vol. 5, 705-709, March 1999
© 1999 American Association for Cancer Research


Cancer Biology, Immunology, Cytokines

Isolation of Human Lymphocyte Antigens Class I-restricted Cytotoxic T Lymphocytes against Autologous Myeloma Cells1

Catherine Pellat-Deceunynck2, Gaëtan Jego, Jean-Luc Harousseau, Henri Vié and Régis Bataille

Institut National de la Santé et de la Recherche Médicale U463 [C. P-D., G. J., J-L. H., H. V., R. B.] and Laboratoire d’Hématologie, [R. B.] Institut de Biologie, 44093 Nantes cedex 01, and Service d’Hématologie Clinique, Hôtel Dieu [J-L. H.], 44035 Nantes cedex 01, France

Peripheral blood T cells from a patient with multiple myeloma in complete remission were selected in vitro against an autologous myeloma cell line (SBN-1), using a protocol designed for the selection of relatively rare precursor cytotoxic T cells (pCTL). Delayed addition (2 weeks) of interleukin 2 induced T-cell proliferation, and a bulk culture (T-cell line) was obtained 2 days later. This T-cell line displayed cytotoxicity against SBN-1. A CD8+ CD4- cytotoxic T-cell clone (CT5) was then obtained that recognized SBN-1 but not autologous EBV+ B-lymphoblastoid cells, autologous T PHA-blasts, or Daudi, Raji, K562, and 11 allogeneic myeloma cell lines. Moreover, CT5 cytotoxic activity against SBN-1 was blocked by monoclonal antibodies recognizing human lymphocyte antigen class I molecules. This seems to be the first demonstration of myeloma-specific pCTL in peripheral blood T cells of patients with multiple myeloma.




This article has been cited by other articles:


Home page
J. Immunol.Home page
M. Condomines, D. Hose, P. Raynaud, M. Hundemer, J. De Vos, M. Baudard, T. Moehler, V. Pantesco, M. Moos, J.-F. Schved, et al.
Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis
J. Immunol., March 1, 2007; 178(5): 3307 - 3315.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
A. Geffroy-Luseau, A. Moreau-Aubry, R. Bataille, and C. Pellat-Deceunynck
Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells
Int. Immunol., September 1, 2005; 17(9): 1193 - 1200.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.